Aortic arch defects

This phase 2 trial tests whether secukinumab, a drug that blocks IL-17A, can help people with active severe Takayasu arteritis achieve remission and stop taking steroids. About 52 participants will receive either secukinumab injections or standard care (like TNF inhibitors). The …

This study tests two new drugs, vunakizumab and ivarmacitinib, for people with active Takayasu arteritis (TAK), a rare disease that causes inflammation in large blood vessels. The trial will enroll 180 adults aged 18-70 whose disease is still active despite standard treatments. R…

This study tests whether adding pirfenidone, a drug used for lung and liver scarring, to standard treatment can improve blood vessel damage in people with Takayasu arteritis. About 92 adults aged 18-60 will receive either pirfenidone or a placebo for 6 months. The goal is to see …

This study will test a new type of PET/CT scanner, called Long-Axial Field-of-View (LAFOV), to see if it can provide clearer images of blood vessel inflammation in people with large vessel vasculitis (LVV). The scanner is more sensitive and can image the whole body faster, potent…

This study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…

This study will test whether a special ultrasound score, called OTUS, can accurately track disease activity in people with Takayasu arteritis, a rare condition that causes inflammation of the large arteries. Researchers will follow 100 patients with active disease, performing ult…